Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John V Heymach

Showing results (1-10 of 478) with videos related to

Pageof 48
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesPetros Nikolinakos, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Angiogenesis inhibitors for lung cancer: clinical developments and future directionsGeorge Blumenschein, John V Heymach
The Oncologist|January 5, 2021
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung CancerXiuning Le, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Vascular endothelial growth factor (VEGF) pathwayMonique Nilsson, John V Heymach
Oncotarget|November 16, 2017
Taking it up a NOTCH: a novel subgroup of ACC is identifiedRenata Ferrarotto, John V Heymach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2015
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?Tina Cascone, John V Heymach
Clinical Lung Cancer|April 28, 2006
Emerging antiangiogenic agents in lung cancerDavid Lee, John V Heymach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?Tina Cascone, John V Heymach
Nature Reviews. Cancer|August 14, 2019
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapyFerdinandos Skoulidis, John V Heymach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
The convergent development of molecular-targeted drugs for cancer treatment and preventionScott M Lippman, John V Heymach
Pageof 48

Showing results (1-10 of 478) with videos related to

Sort By:
Pageof 48
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesPetros Nikolinakos, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Angiogenesis inhibitors for lung cancer: clinical developments and future directionsGeorge Blumenschein, John V Heymach
The Oncologist|January 5, 2021
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung CancerXiuning Le, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Vascular endothelial growth factor (VEGF) pathwayMonique Nilsson, John V Heymach
Oncotarget|November 16, 2017
Taking it up a NOTCH: a novel subgroup of ACC is identifiedRenata Ferrarotto, John V Heymach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2015
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?Tina Cascone, John V Heymach
Clinical Lung Cancer|April 28, 2006
Emerging antiangiogenic agents in lung cancerDavid Lee, John V Heymach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?Tina Cascone, John V Heymach
Nature Reviews. Cancer|August 14, 2019
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapyFerdinandos Skoulidis, John V Heymach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
The convergent development of molecular-targeted drugs for cancer treatment and preventionScott M Lippman, John V Heymach
Pageof 48